Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COVID-2019 immune globulins - Emergent BioSolutions

Drug Profile

COVID-2019 immune globulins - Emergent BioSolutions

Alternative Names: Anti-SARS-CoV-2 immune globulin intravenous (Human); COVID-HIG

Latest Information Update: 14 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Emergent BioSolutions
  • Developer Emergent BioSolutions; National Institute of Allergy and Infectious Diseases
  • Class Antivirals; Immunoglobulins; Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III COVID 2019 infections

Most Recent Events

  • 09 Oct 2020 Emergent BioSolutions also plans a clinical trial for post exposure prevention prophylaxis therapeutic in COVID-2019 infections who are at high risk of exposure
  • 30 Sep 2020 Phase-III clinical trials in COVID-2019 infections in United Kingdom (IV) (EudraCT-2020-002542-16)
  • 31 Aug 2020 Emergent BioSolutions and National Institute of Allergy and Infectious Diseases receives IND approval from the US FDA for use of COVID-HIG in the ITAC study
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top